Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 428

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Prof Daniel Petrylak talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a study looking at the novel agent enfortumab vedotin targeting Nectin-4 as treatment for patients with advanced urothelial cancer.

He explains that Nectin-4 is a protein that helps cancer cells stick together and it is expressed in 97% urothelial cancers.

Prof Petrylak reports that overall 44% of patients who received the targeting agent responded to treatment and also that a response was seen across the different subgroups.

Watch the press conference here.

Read the news story here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

18.06.19

no rating
Cancer care in Latin America

follow us

WIN 2019


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation